

5143
D6
CON4
BS
Out

protein receptor is selected from the group consisting of an Hsp70 receptor, an Hsp 90 receptor, and a gp96 receptor.

78. (new) The method of claim 51, 52, 69, 70, 71, 74, 75, or 76, wherein the heat shock protein receptor positive cells are purified from heat shock protein receptor negative cells.

IN THE SPECIFICATION:

Please amend the specification as follows:

Replace the Table of Contents on pages i-iii with the following version of the Table of Contents:

PURIFICATION OF HEAT SHOCK/STRESS PROTEIN CELL SURFACE
RECEPTORS AND THEIR USE AS IMMUNOTHERAPEUTIC AGENTS

1. Introduction
2. Background Of The Invention
- 2.1. Heat Shock Proteins
 - 2.2. Immunogenicity of HSP-Peptide Complexes
 - 2.3. Immunotherapeutic HSP-Antigen Complexes
 - 2.4. Antigen Presentation of HSP-peptide Complexes
3. Summary Of The Invention
4. Brief Description Of The Figures
5. Detailed Description Of The Invention
- 5.1 Purification of HSP Receptor Positive Cells
 - 5.2 Preparation of HSPs and HSP-peptide Complexes
 - 5.2.1 Preparation and Purification of Hsp70-peptide Complexes
 - 5.2.2 Preparation and Purification of Hsp90-peptide Complexes
 - 5.2.3 Preparation and Purification of gp96-peptide Complexes
 - 5.2.4 Labeling of HSPs and HSP peptide complexes
 - 5.2.5 Isolation Of HSPR Positive Cells
 - 5.3 HSP Receptor Protein
 - 5.3.1 Purification of HSP Receptor Protein
 - 5.4 Generation of Antibodies Against The HSP Receptor
 - 5.5 Isolation of HSP Receptor Gene Sequences
 - 5.5.1 Preparation of mRNA and cDNA
 - 5.5.2 Identification of HSPR Gene Sequences by Differential Expression Methods

- B6
Annotated
- 5.5.3 Preparation of a cDNA Library
 - 5.5.4 Subtractive Hybridization
 - Expression Methods
 - 5.5.5 Screening Of Gene Library
 - 5.5.6 cDNA Expression Cloning in
Eukaryotic Cells
 - 5.6 Expression of HSPR Genes
 - 5.7 Assays For The Identification Of Compounds That
Modulate The Activity Of The HSP Receptor
 - 5.8 Assays To Identify HSPR Agonists And
Antagonists
 - 5.9 Assays For The Identification Of Compounds That
Modulate The Interaction Of The HSP Receptor With
Other Proteins
 - 5.11 Methods And Compositions For Therapeutic Use
Of HSP Receptor Protein, Derivatives, And Modulators
 - 5.11.1 Therapeutic Use Of Identified Agonists
And Antagonists
 - 5.11.2 Gene Replacement Therapy
 - 5.12 Target Infectious Diseases
 - 5.13 Target Proliferative Cell Disorders
 - 5.14 Pharmaceutical Preparations And
Methods Of Administration
 - 5.14.1 Effective Dose
 - 5.14.2 Formulations And Use
 - 6. Example: Identification Of gp96 Receptor
 - 6.1 Introduction
 - 6.2 Materials and Methods
 - 6.3 Results
 - 7. Expression Cloning Of The HSP Receptor
 - 7.1. Panning Method
 - 8. Production Of Antibody And Isolation Of The gp96 Receptor By
Antibody Binding

Delete the section of the application entitled "ABSTRACT" and replace it with the following section:

ABSTRACT

BM
The present invention relates to receptors for heat shock proteins (HSPs), such as gp96, Hsp70 and Hsp90. The heat shock receptor is associated with the cell membranes of a subset of antigen presenting cells, such as macrophages and dendritic cells. The present invention relates to the use of the heat shock protein receptor positive cells, heat shock protein receptor protein, and heat shock protein receptor genes in methods for screening a molecule for the ability to modulate heat shock protein levels or activities.

Delete the section of the application entitled Brief Description of the Figures which appears on pages 9 and 10, and replace it with the following replacement Section:

4. Brief Description Of The Figures

SUB
C1
Figure 1A-1E. gp96 receptor positive cells. A) Light microscopy, or B) confocal microscopy of gp96 bound to membranes of peritoneal cells of C57/BL6 mice. C) Negative control, unlabeled. D) Negative control, labeled with BSA-biotin. E) gp96-biotin labeled.

BS
Figure 2A-2C. Time course of gp96-biotin internalization by peritoneal cells of C57/BL6 mice. A) Top left panel, light microscopy of a peritoneal cell, followed by confocal microscopy of a time course of gp96-biotin uptake by the same cell at 37°C, shown after 0, 2, 4, 6, 8, 10, 12, or 14 mins. B) Left panel, light microscopy of a peritoneal cell, followed by a confocal microscopy time course of gp96-biotin uptake by the same cell at 4°C, labeled for 0, and 120 mins.

Sub
C'
cont

Figure 3A-3E. gp96 receptor positive cells. A) Light microscopy, or B) confocal microscopy of gp96 bound to membranes of peritoneal cells of the transgenic mouse ImmortoMouse. C) Negative control, unlabeled. D) Negative control, labeled with BSA-biotin. E) gp96-biotin labeled.

BS
cont

Figure 4. FacScan analysis of Hsp90 (column 1), gp96 (column 2), Hsp70 (column 3), and BSA (column 4) labeled with FITC and pulsed on to Mac-1 positive cells (macrophage) at HSP concentrations of 10 $\mu\text{g/ml}$ (row 1), 20 $\mu\text{g/ml}$ (row 2), 50 $\mu\text{g/ml}$ (row 3), 100 $\mu\text{g/ml}$ (row 4), and 190 $\mu\text{g/ml}$ (row 5). X axis measures FITC absorbence; Y axis measures propidium iodine (PI) absorbence.

Figure 5. HSP Receptor saturation by ^{125}I -labeled gp96 in BALB/C Mac-1+ cells and C57BL/6 Mac-1+ (macrophage) cells. ^{125}I -labeled BSA is shown as a negative control.